Skip to main content
SpringerLink
Log in

Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine

  • Original Articles
  • Vinblastine
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Ten patients with advanced cancer were treated in a phase-1 trial with monthly cycles of a 5-day infusion of vinblastine. Serum drug levels were relatively constant after 24 h and there was no correlation between drug level and myelo-suppression or toxicity. Previously underscribed toxicities were observed, including one hypersensitivity reaction and three cases of severe, only slowly reversible, sensorimotor neuropathy. Two patients showed objective tumor regression during the vinblastine infusion therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bodey CP, Yap H-Y, Yap B-S, Valdivieso M (1980) Continuous-infusion vindesine in solid tumors. Cancer Treat Rev [Suppl] 7: 39

    Google Scholar 

  2. Chirife AM, Studzinski GP (1978) Definition of the cell cycle segment with special sensitivity to vinblastine. Proc Soc Exp Biol Med 157: 206

    Google Scholar 

  3. Hande K, Gay J, Gober J Greco FA (1980) Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusion. Cancer Treat Rev [Suppl] 7: 25

    Google Scholar 

  4. Jackson DV, Sethi VS, Spurr CL, et al. (1981) Intravenous vincristine infusion: phase I trial. Cancer 48: 2559

    Google Scholar 

  5. Nelson RL, Dyke RW, Root MA (1980) Comparative pharmacokinetics of vindesine, vincristine, and vinblastine in patients with cancer. Cancer Treat Rev [Suppl] 7: 17

    Google Scholar 

  6. Owellen RJ, Hartke CA, Hains FO (1977) Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 37: 2597

    Google Scholar 

  7. Schulman P, Budman DR, Vinciguerra V, Degman TJ (1980) Phase I evaluation of divided-dose vinblastine sulfate. Cancer Chemother Pharmacol 5: 67

    Google Scholar 

  8. Sethi VS, Burton SS, Jackson DV (1980) A sensitive radioimmunoassay for vincristine and vinblastine. Cancer Chemother Pharmacol 4: 183

    Google Scholar 

  9. Thant M, Hawley RT, Smith MT, et al (1982) Possible enchancement of vincristine neuropathy by VP-16. Cancer 49: 859

    Google Scholar 

  10. Yap H-Y, Blumenschein GR, Keating MJ, et al (1980) Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep 64: 279

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, 92103, San Diego, CA, USA

    James A. Young, Stephen B. Howell & Mark R. Green

  2. the University of California San Diego Cancer Center, 92103, San Diego, CA, USA

    James A. Young, Stephen B. Howell & Mark R. Green

Authors
  1. James A. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen B. Howell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark R. Green
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Young, J.A., Howell, S.B. & Green, M.R. Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine. Cancer Chemother. Pharmacol. 12, 43–45 (1984). https://doi.org/10.1007/BF00255908

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00255908

Keywords

Search

Navigation